A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs SUVN 502 (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Sponsors Suven Life Sciences
- 06 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 06 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017